As per our report, the size of the global intravenous ibuprofen market was worth USD 6.86 billion in 2020. This figure is estimated to be growing at a CAGR of 20.0% and will reach USD 17.07 billion by 2025.
Intravenous ibuprofen is the type of parenteral dosage form containing anti-inflammatory action that can protect from infective agents. It is a non-steroid anti-inflammatory agent which inhibits the functions of cyclooxygenase COX-1 and COX-2 enzymes that control the synthesis of prostaglandins. Ibuprofen injection is also used to reduce pain in the menstrual cycle. The Food and Drug Administration has approved caldolor ibuprofen for paediatrics as well as adult patients.
MARKET DRIVERS
The major factors driving the growth of intravenous ibuprofen market are high bioavailability with rapid action, increasing diseases like CVS, osteoarthritis, rheumatoid arthritis, cancer and headache. Easy availability of ibuprofen on over the counter across the world is enhancing market growth. Increasing awareness about rapid pain relief injections and pharmaceutical industries are focussing on the development of innovative drugs are accelerating the demand of the market. Also, the rise in the disposable income in the urban areas is levelling up the growth rate of the market.
MARKET RESTRAINTS
However, due to the side effects of intravenous ibuprofen injection in the market, and it takes a long time to introduce new products in the market are some factors hampering the Intravenous ibuprofen global market. Due to the implementation and advancement in technology as well as investing for R&D, it will foresee a growth of ibuprofen injection market.
REPORT COVERAGE
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Analysed |
By Age Group, Indication and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Analysed |
North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
This research report on the Global Intravenous Ibuprofen Market has been segmented based on the age group, indication and region.
Intravenous Ibuprofen Market – By Age group
Based on the age group, the Adults are the significant consumer base for intravenous ibuprofen. The paediatric segment is expected to grow at a substantial rate. The Pediatrics segment is estimated to be the quickest growing segment during the forecast period. Increasing awareness about the Intravenous ibuprofen and increasing funds from the government organizations are some factors escalating market growth.
Intravenous Ibuprofen Market - By Indication
Based on the Indication, the fever segment is projected to grow at the most significant share from 2019 to 2024. Rising incidences of chronic diseases are propelling the demand of the market.
Regional Insights
In 2019, the North America region was the most dominated and the largest market share of intravenous ibuprofen. In this region, the U.S. and Canada are estimated to remain as the highest income-producing region. The growth of this market is credited due to extensive obtainment of intravenous ibuprofen used for treating people suffering from pain and fever.
Europe intravenous ibuprofen market is estimated to grow at a CAGR value of 19.23% during the forecast period and has occupied the second largest market share. Increasing awareness among the people, particularly in adults and Soaring occurrences of heart-related disorders and cancer are significantly driving the market.
Asia-Pacific is expected to grow with the highest CAGR value during the period. Rising awareness of non-steroidal anti-inflammatory drugs and transferring tendency associated with intravenous mode of drug delivery are fuelling the growth rate of the market. The Australian region is expected to grow high with a CAGR of 14.7% during the period.
Latin America is evaluated to grow prominently during the period. Increasing occurrences of cardiovascular diseases and growing support from the government are escalating the intravenous ibuprofen market growth.
The Middle East & Africa intravenous market is expected to reach USD 1.55billion by 2024 during the period. This region is attributed due to owing factors like pain, fever, headache, toothache, back pain, and trauma.
TOP COMPANIES IN THE MARKET
Some of the major companies dominating the Global Intravenous Ibuprofen Market profiled in the report are Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc., CSL Limited, Sandor Medicaids Pvt Ltd., Germin MED, Grifols S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Al Nabeel International Ltd., PT. Soho Industri Pharmasi and Laboratorios Valmorca, C.A.
RECENT MARKET DEVELOPMENTS
On January 07, 2020, Cumberland, a pharmaceutical company announced new products caldolor for the treatment of acute care. The latest version of caldolor is taken directly without dilution for pain relief. Caldolor is an anti-inflammatory agent that helps to reduce mild-moderate pain.
In 2020, the Cumberland pharmaceuticals initiated the expansion of their caldolor business in the world for the treatment of coronavirus infections. The company provides support through caldolor access to the hospitals and clinic in various countries.
In 2020, Nashville pharmaceutical company might be reducing opioid use with launching new product ibuprofen in an IV bag in the market. This IV bag helps to decrease the need for the opioid analgesic drug for post-surgery.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Age group
5.1.1 Introduction
5.1.2 Paediatrics
5.1.3 Adults
5.1.4 Y-o-Y Growth Analysis, By age group
5.1.5 Market Attractiveness Analysis, By age group
5.1.6 Market Share Analysis, By age group
5.2 Indication
5.2.1 Introduction
5.2.2 Pain/inflammatory
5.2.3 Fever
5.2.4 Y-o-Y Growth Analysis, By Indication
5.2.5 Market Attractiveness Analysis, By Indication
5.2.6 Market Share Analysis, By Indication
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By age group
6.1.3.3 By indication
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By age group
6.1.4.3 By indication
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By age group
6.1.5.3 By indication
6.2 North America
6.2.1 Introduction
6.2.2 United States
6.2.3 Canada
6.3 Europe
6.3.1 Introduction
6.3.2 U.K
6.3.3 Spain
6.3.4 Germany
6.3.5 Italy
6.3.6 France
6.4 Asia-Pacific
6.4.1 Introduction
6.4.2 China
6.4.3 India
6.4.4 Japan
6.4.5 Australia
6.4.6 South Korea
6.5 Latin America
6.5.1 Introduction
6.5.2 Brazil
6.5.3 Argentina
6.5.4 Mexico
6.5.5 Rest of Latin America
6.6 Middle East & Africa
6.6.1 Introduction
6.6.2 Middle-East
6.6.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Cumberland Pharmaceuticals Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Alveda Pharmaceuticals, Inc.
8.3 CSL Limited
8.4 Sandor Medicaids Pvt Ltd.
8.5 Germin MED
8.6 Grifols S.A.
8.7 Harbin Gloria Pharmaceuticals Co.Ltd.
8.8 Al Nabeel International Ltd.
8.9 Laboratorios Valmorca, C.A.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
